skip to Main Content
Get Board Certified
BECOME CERTIFIED
Overview
Board Eligibility
Fees
FAQs
Candidate Handbook
ABOUT THE EXAM
BCMTMS™ Exam Overview
Examination Scheduling
Testing Dates
Exam Content Outline
Exam Prep Resources
Handbook
test
APPLY NOW
Maintain Certification
MAINTAIN CERTIFICATION
Renewal Cycle
Recertification Process
Recertification Handbook
MTM Certificate
Menu 3
About
ABOUT NBMTM
Mission, Vision & Values
History
Leadership & Governance
Accreditation
Volunteer Opportunities
ABOUT OUR CERTIFICATION
MTM Certification
BCMTMS
A Trusted Credential
Reports and Pass Rates
my
NBMTM
Search
Search
Submit
Menu
Feed Items
Home
|
Factors reducing omalizumab response in severe asthma
Factors reducing omalizumab response in severe asthma
February 6, 2018
Factors reducing omalizumab response in severe asthma
Published on 02/05/2018
Tweet
Share
Share
previous post:
Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand
next post:
Outcomes of endoscopic intervention for overt gastrointestinal bleeding in severe thrombocytopenia
Get Board Certified
Overview
Board Eligibility
BCMTMS™ Exam Overview
Testing Dates
Fees
Exam Content Outline
Exam Prep Resources
Candidate Handbook
Maintain Certification
Renew Certification
Renewal Cycle
Recertification Process
Recertification Handbook
About
Mission, Vision & Values
History
Leadership & Governance
Accreditation
MTM Certification
A Trusted Credential
Login
Back To Top
